• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Longeveron Inc.

    4/28/25 5:07:29 PM ET
    $LGVN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $LGVN alert in real time by email
    DEFA14A 1 ea0237609-04.htm ADDITIONAL MATERIALS

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    _________________

    SCHEDULE 14A

    _________________

    PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE
    SECURITIES EXCHANGE ACT OF 1934

    Filed by the Registrant

     

    ☒

    Filed by a Party other than the Registrant

     

    ☐

    Check the appropriate box:

    ☐

     

    Preliminary Proxy Statement

    ☐

     

    Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

    ☐

     

    Definitive Proxy Statement

    ☒

     

    Definitive Additional Materials

    ☐

     

    Soliciting Material under 240.14a-12

    Longeveron Inc.
    (Name of Registrant as Specified In Its Charter)

    _________________________________________________________________

    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)

    Payment of Filing Fee (Check the appropriate box):

    ☒

     

    No fee required.

    ☐

     

    Fee paid previously with preliminary materials.

    ☐

     

    Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.

     

    Longeveron Inc. 1951 NW 7th Avenue, Suite 520 Miami, Florida 33136 Important Notice Regarding the Availability of Proxy Materials for the Stockholder Meeting to be Held on Friday, June 13, 2025 «FName» «Address12» «Address3» «COUNTRY» Control #: «ControlNumberExt» As part of our efforts to conserve environmental resources and prevent unnecessary corporate expenses, Longeveron Inc. has elected to provide Internet access to its proxy statement, proxy voting card, proxy notice and annual report rather than mailing paper copies. This reduces postage, printing expenses, and unnecessary paper waste. This is not a ballot. You cannot use this notice to vote these shares. This communication presents only an overview of the more complete proxy materials that are available to you on the Internet or by mail. We encourage you to access and review all of the important information contained in the proxy materials before voting. Voting Items The board of directors of Longeveron Inc. recommends a vote FOR the director nominee in Proposal 1 and FOR Proposals 2, and 3. Your Proxy, when properly executed, will be voted in the manner directed herein by the undersigned stockholder. If no direction is given, your Proxy will be voted FOR the director nominee in Proposal 1 and FOR Proposals 2 and 3. 1. Director Election Nominee: a. Rock Soffer 2. Approval of an amendment to the Second Amended and Restated Longeveron Inc. 2021 Incentive Award Plan 3. Ratification of the appointment of CBIZ CPAs P.C. as Longeveron’s independent registered public accounting firm for the year ending December 31, 2025 HOW TO ACCESS THE PROXY MATERIALS The proxy statement, proxy voting card, proxy notice, and annual report to security holders are available online at: www.colonialstock.com/longeveron2025 HOW TO VOTE BY INTERNET www.colonialstock.com/longeveron2025 On the above website, you can vote by clicking “Vote” and then entering the control number above as directed. BY PHONE 877-285-8605 BY MAIL Send a paper proxy voting card by mail. You may request a proxy card by contacting us at 877-285-8605. MEETING INFORMATION Meeting Type: Annual Meeting Meeting Date: June 13, 2025 1:00 PM EDT Meeting Location: To be held virtually at: www.colonialstock.com/longeveron2025 TO ORDER A PAPER OR E-MAIL COPY OF THE PROXY MATERIALS: If you want to receive a paper or e-mail copy of these documents for this and/or future stockholder meetings, you must request one. There is no charge to you for requesting a copy. To facilitate timely delivery, please make your request for a copy as instructed below on or before: June 3, 2025 1. By Phone: (877) 285-8605 2. By Internet: www.colonialstock.com/longeveron2025 3. By Email: [email protected] If requesting materials by email, please include the control number listed above with your request. Unless requested, you will not otherwise receive a paper or e-mail copy of these materials.

     

    Get the next $LGVN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $LGVN

    DatePrice TargetRatingAnalyst
    12/6/2024$10.00Buy
    ROTH MKM
    1/5/2022$20.00Buy
    EF Hutton
    More analyst ratings

    $LGVN
    SEC Filings

    View All

    Longeveron Inc. filed SEC Form 8-K: Leadership Update

    8-K - Longeveron Inc. (0001721484) (Filer)

    11/12/25 6:20:54 AM ET
    $LGVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Longeveron Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Longeveron Inc. (0001721484) (Filer)

    11/4/25 4:15:18 PM ET
    $LGVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Longeveron Inc.

    10-Q - Longeveron Inc. (0001721484) (Filer)

    11/4/25 4:00:55 PM ET
    $LGVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LGVN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Longeveron Applauds Passage of the Mikaela Naylon Give Kids a Chance Act and Reauthorization of Rare Pediatric Disease Priority Review Voucher Program

    The Mikaela Naylon Give Kids a Chance Act reauthorizes the Pediatric Priority Review Voucher (PPRV) Program and extends eligibility for medicines achieving U.S. FDA approval before September 2029The Pediatric Priority Review Voucher program encourages the development of treatments for rare pediatric diseasesU.S. FDA has awarded Longeveron's laromestrocel Hypoplastic Left Heart Syndrome (HLHS) program Rare Pediatric Disease designation, Orphan Drug designation, and Fast Track designationWith the extension of the PPRV Program, Longeveron may be granted a Priority Review Voucher if laromestrocel's Biological License Application (BLA) is approved by the FDA before September 2029 MIAMI, Feb. 05

    2/5/26 9:15:00 AM ET
    $LGVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Longeveron® Granted Japan Patent for Potency Assay Methods for Assessing Human Mesenchymal Stem Cells (MSCs)

    The patent relates to potency assay methods for assessing human mesenchymal stem cells (MSCs) derived from bone marrow, adipose tissue, peripheral blood, a lung, a heart, amniotic fluid, inner organs, an amniotic membrane, an umbilical cord or a placenta or differentiated from induced pluripotent stem cells (IPSCs)Patent issuance contributes to Longeveron's growing international patent portfolio protecting its clinical programs and productsLaromestrocel, Longeveron's proprietary mesenchymal stem cell therapy, has delivered positive initial results across five clinical trials in three indications, including Hypoplastic Left Heart Syndrome, Alzheimer's disease and Aging-related Frailty MIAMI,

    1/29/26 9:15:00 AM ET
    $LGVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Longeveron Announces FDA Grants Type C Meeting Ahead of Data Readout for Pivotal Phase 2 Clinical Trial (ELPIS II) Evaluating Treatment for Hypoplastic Left Heart Syndrome (HLHS)

    ELPIS II top-line trial results are anticipated in the third quarter of 2026Laromestrocel Biological License Application (BLA) submission for full traditional approval for HLHS anticipated if ELPIS II results are positiveU.S. FDA has awarded laromestrocel HLHS program Rare Pediatric Disease designation, Orphan Drug designation, and Fast Track designationLaromestrocel HLHS program has the potential to address an unmet medical need with significant U.S. market opportunitiesEven with current standard of care surgeries, only 50% of infants survive to adolescence due to right ventricular failure MIAMI, Jan. 26, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN), a clinical stage biotechnol

    1/26/26 9:15:00 AM ET
    $LGVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LGVN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Locklear Lisa covered exercise/tax liability with 10,250 shares, decreasing direct ownership by 4% to 228,831 units (SEC Form 4)

    4 - Longeveron Inc. (0001721484) (Issuer)

    1/6/26 6:00:19 PM ET
    $LGVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Medical Officer Agafonova Nataliya covered exercise/tax liability with 10,250 shares, decreasing direct ownership by 5% to 216,564 units (SEC Form 4)

    4 - Longeveron Inc. (0001721484) (Issuer)

    1/6/26 6:00:23 PM ET
    $LGVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    General Counsel, Secretary Lehr Paul T covered exercise/tax liability with 6,952 shares, decreasing direct ownership by 2% to 344,177 units (SEC Form 4)

    4 - Longeveron Inc. (0001721484) (Issuer)

    1/6/26 6:00:21 PM ET
    $LGVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LGVN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Baluch Khoso bought 11,766 shares, increasing direct ownership by 29% to 52,516 units (SEC Form 4)

    4 - Longeveron Inc. (0001721484) (Issuer)

    8/13/25 6:00:07 PM ET
    $LGVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Financial Officer Locklear Lisa bought 11,766 shares, increasing direct ownership by 5% to 250,964 units (SEC Form 4)

    4 - Longeveron Inc. (0001721484) (Issuer)

    8/13/25 6:00:08 PM ET
    $LGVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Hare Joshua bought $350,000 worth of shares (148,936 units at $2.35), increasing direct ownership by 31% to 633,280 units (SEC Form 4)

    4 - Longeveron Inc. (0001721484) (Issuer)

    4/12/24 7:00:29 PM ET
    $LGVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LGVN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    ROTH MKM initiated coverage on Longeveron with a new price target

    ROTH MKM initiated coverage of Longeveron with a rating of Buy and set a new price target of $10.00

    12/6/24 7:54:21 AM ET
    $LGVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    EF Hutton initiated coverage on Longeveron with a new price target

    EF Hutton initiated coverage of Longeveron with a rating of Buy and set a new price target of $20.00

    1/5/22 10:22:40 AM ET
    $LGVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LGVN
    Financials

    Live finance-specific insights

    View All

    Longeveron® to Report Third Quarter 2025 Financial Results and Host Conference Call on November 4, 2025

    MIAMI, Oct. 28, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN), a clinical stage biotechnology company developing cellular therapies for life-threatening, rare pediatric and chronic aging-related conditions, today announced that it will report third quarter 2025 financial results and provide a business update on Tuesday, November 4, 2025 after the U.S. financial markets close. The Company will host a conference call and webcast the same day at 4:30 p.m. ET. Conference Call and Webcast Details:   Conference Call Number: 1.877.407.0789Conference ID: 13755997   Call me™ Feature: Click HereWebcast: Click Here An archived replay of the webcast will be available on the "Events & Presenta

    10/28/25 9:15:00 AM ET
    $LGVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Longeveron® to Report Second Quarter 2025 Financial Results and Host Conference Call on August 13, 2025

    MIAMI, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening, rare pediatric and chronic aging-related conditions, today announced that it will report second quarter 2025 financial results and provide a business update on Wednesday, August 13, 2025 after the U.S. financial markets close. The Company will host a conference call and webcast the same day at 4:30 p.m. ET. Conference Call and Webcast Details:  Conference Call Number:1.877.407.0789Conference ID:13754295  Call meTM Feature:Click HereWebcast:Click Here   An archived replay of the webcast will be available on t

    8/5/25 9:15:00 AM ET
    $LGVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Longeveron® Announces First Quarter 2025 Financial Results and Provides Business Update

    Pivotal Phase 2b clinical trial (ELPIS II) evaluating laromestrocel in HLHS, a rare pediatric disease and orphan-designated indication, has reached approximately 95% enrollment and is expected to complete enrollment in the second quarter of 2025Laromestrocel Biological License Application (BLA) submission for full traditional approval for HLHS anticipated in 2026, if ELPIS II is successfulResults from the Phase 2a clinical trial (CLEAR MIND) evaluating laromestrocel as a potential treatment for Alzheimer's disease were published in Nature MedicinePositive FDA meeting regarding development pathway for laromestrocel in mild Alzheimer's disease; single, pivotal Phase 2/3 adaptive design clinica

    5/8/25 4:05:00 PM ET
    $LGVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LGVN
    Leadership Updates

    Live Leadership Updates

    View All

    George Paletta, Jr., MD, MBA, Internationally Acclaimed Entrepreneur, Investor and Surgeon, Elected to Longeveron® Board of Directors

    MIAMI, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN), a clinical stage biotechnology company developing cellular therapies for life-threatening, rare pediatric and chronic aging-related conditions, today announced that George Paletta, Jr., MD, MBA, has been elected to the Longeveron Board of Directors. Dr. Paletta is a nationally and internationally recognized orthopedic surgeon and the head team doctor for the St. Louis Cardinals. Dr. Paletta is a developer of ambulatory surgical centers (ASCs), and has participated in the selling of two ASCs with deal values totaling almost $1 billion. "I am delighted to welcome George, and his tremendous experience as a physician, inv

    10/1/25 4:05:00 PM ET
    $LGVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Longeveron® Appoints Than Powell as Chief Business Officer

    Mr. Powell to oversee Longeveron's partnering and international strategy efforts MIAMI, June 26, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced that it has appointed Than Powell as Chief Business Officer, effective July 7, 2025. In this role, he will lead the Company's overall business strategy, Alzheimer's disease program partnering efforts, and international strategy for the hypoplastic left heart syndrome (HLHS) program. "We are delighted to have Than join Longeveron at this transformational time in the Company's

    6/26/25 9:05:00 AM ET
    $LGVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Longeveron® Appoints Devin Blass as Chief Technology Officer and SVP of Chemistry, Manufacturing and Controls (CMC)

    MIAMI, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced that it has appointed Devin Blass as Chief Technology Officer (CTO) and Senior Vice President of Chemistry, Manufacturing, and Controls (CMC), effective December 2, 2024. In this role, he will lead the Company's technological and manufacturing strategies. "We are delighted to have Devin join Longeveron at this transformational time in the Company's evolution," said Wa'el Hashad, Chief Executive Officer at Longeveron. "This appointment reinforces Longevero

    11/11/24 9:05:00 AM ET
    $LGVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LGVN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Longeveron Inc.

    SC 13G/A - Longeveron Inc. (0001721484) (Subject)

    11/14/24 4:20:18 PM ET
    $LGVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Longeveron Inc.

    SC 13G - Longeveron Inc. (0001721484) (Subject)

    7/26/24 4:18:08 PM ET
    $LGVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Longeveron Inc.

    SC 13G - Longeveron Inc. (0001721484) (Subject)

    4/17/24 4:03:33 PM ET
    $LGVN
    Biotechnology: Pharmaceutical Preparations
    Health Care